Divestiture streamlines operations and advances the Company's strategy to fully exit non-core activities

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience's operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry.

LGC Standards is a division of LGC Group, a global leader in life sciences, diagnostics, and analytical solutions. The LGC Standards business provides reference materials, research chemicals, and proficiency testing to ensure accuracy and reliability in laboratories and manufacturing.